Breast Cancer Portal of Bangladesh

Oncology Dictionary

Instant, high-precision reference for clinical short forms, genomic biomarkers, molecular subtypes, diagnostic tests, and surgical regimens in breast cancer care.

Categories:
A–Z:
Showing 109 terms
Acronyms & Short Forms

BCPBD

Breast Cancer Portal of Bangladesh

The national biomedical research portal and clinical data repository aggregating epidemiological, clinical, and genomic data from Bangladeshi breast cancer patients to support translational oncology and precision care.

Clinical Relevance:

Developed by the Department of Genetic Engineering & Biotechnology at the University of Dhaka, BCPBD provides native datasets, statistical calculators, and TCGA-integrated research tools tailored to the Bangladeshi and South Asian population.

Related:
Acronyms & Short Forms

TNBC

Triple-Negative Breast Cancer

A breast cancer subtype whose tumor cells lack estrogen receptors (ER-), progesterone receptors (PR-), and human epidermal growth factor receptor 2 (HER2-).

Clinical Relevance:

Comprises approximately 15-20% of cases worldwide but exhibits higher prevalence in South Asian populations. Does not respond to endocrine therapy or HER2-targeted agents; managed primarily with chemotherapy, PARP inhibitors, and immunotherapy.

Related:
Acronyms & Short Forms

ER

Estrogen Receptor

A nuclear hormone receptor protein that binds estrogen hormones. When breast cancer cells test positive for ER (ER+), estrogen stimulates their growth and survival.

Clinical Relevance:

Expressed in approximately 70-80% of breast cancer diagnoses. Serves as the primary biomarker for prescribing endocrine therapies such as Tamoxifen and Aromatase Inhibitors.

Related:
Acronyms & Short Forms

PR

Progesterone Receptor

An intracellular steroid receptor regulated by estrogen and activated by progesterone. Tested alongside ER during routine immunohistochemical profiling.

Clinical Relevance:

PR expression reflects a functionally intact estrogen signaling pathway. High PR positivity combined with ER positivity is indicative of the favorable Luminal A subtype.

Related:
Acronyms & Short Forms
HER2

HER2 / neu

Human Epidermal Growth Factor Receptor 2 (ERBB2)

A receptor tyrosine kinase encoded by the ERBB2 oncogene on chromosome 17q. Promotes cellular proliferation and inhibits apoptosis when overexpressed or amplified.

Clinical Relevance:

Amplified or overexpressed in 15-20% of invasive breast carcinomas. Targeted directly with monoclonal antibodies (Trastuzumab, Pertuzumab) and antibody-drug conjugates (T-DXd).

Related:
Acronyms & Short Forms
TNM

TNM Staging

Tumor, Node, Metastasis Staging System

The globally standard oncology staging classification developed by the AJCC and UICC, evaluating primary Tumor size/extent (T), regional lymph Node metastasis (N), and distant Metastasis (M).

Clinical Relevance:

Forms the bedrock of clinical decision-making, stratifying cancers from Stage 0 (in situ) through Stage IV (distant metastasis) to determine curative versus palliative treatment intent.

Related:
Acronyms & Short Forms

IDC

Invasive Ductal Carcinoma (No Special Type - NST)

Malignant breast carcinoma that originated inside mammary milk ducts and has breached the basement membrane to infiltrate neighboring breast stroma and adipose tissue.

Clinical Relevance:

The single most common histological type of breast cancer, representing 75-80% of all invasive breast cancer diagnoses globally and in the BCPBD registry.

Related:
Acronyms & Short Forms

ILC

Invasive Lobular Carcinoma

Invasive breast cancer arising in the milk-producing lobules, characterized histologically by single-file linear infiltration of discohesive cells due to loss of the cell adhesion protein E-cadherin (CDH1).

Clinical Relevance:

Accounts for 10-15% of breast cancers. Often difficult to palpate and detect on mammography; frequently bilateral and multicentric.

Related:
Acronyms & Short Forms

DCIS

Ductal Carcinoma In Situ

A non-invasive proliferation of malignant-appearing epithelial cells inside the mammary milk ducts without penetration across the epithelial basement membrane.

Clinical Relevance:

Classified as Stage 0 cancer. Frequently diagnosed on screening mammograms via microcalcifications. High cure rate following lumpectomy and radiation.

Related:
Acronyms & Short Forms

LCIS

Lobular Carcinoma In Situ

An atypical non-invasive proliferation of discohesive cells expanding breast lobules without breaching the lobular basement membrane.

Clinical Relevance:

Historically regarded as a pre-cancer, now recognized primarily as a high-risk indicator and marker for subsequent bilateral invasive breast cancer development.

Related:
Acronyms & Short Forms

IBC

Inflammatory Breast Cancer

A rare, fast-progressing, locally advanced breast cancer where malignant cells obstruct dermal lymphatic channels, causing generalized redness, swelling, warmth, and an orange-peel (peau d'orange) skin texture.

Clinical Relevance:

Staged at presentation as Stage IIIB or Stage IV. Requires immediate neoadjuvant chemotherapy before modified radical mastectomy and post-mastectomy radiation.

Related:
Acronyms & Short Forms

MBC

Metastatic Breast Cancer (Stage IV)

Advanced breast cancer that has disseminated through the vascular or lymphatic systems to distant anatomical organs, predominantly bones, lungs, liver, brain, or distant nodes.

Clinical Relevance:

Managed with ongoing systemic therapies (targeted agents, endocrine therapy, chemotherapy, CDK4/6 inhibitors) focused on disease stabilization and extending quality of life.

Related:
Acronyms & Short Forms

FNAC

Fine Needle Aspiration Cytology

A rapid diagnostic procedure using a fine-gauge needle (21-25 gauge) and syringe to extract individual cells and fluid from a palpable breast lump for microscopic cytology.

Clinical Relevance:

Widely used across district and tertiary hospitals in Bangladesh for rapid primary triaging, though core needle biopsy is necessary to confirm invasion and perform receptor IHC.

Related:
Acronyms & Short Forms

CNB

Core Needle Biopsy

A tissue-sampling procedure utilizing a wide-bore spring-loaded needle (14-16 gauge) under local anesthesia to harvest intact cylinders (cores) of solid breast tissue.

Clinical Relevance:

The worldwide gold standard for definitive breast cancer diagnosis. Differentiates in situ from invasive lesions and supplies adequate tissue for ER, PR, HER2, and Ki-67 tests.

Related:
Acronyms & Short Forms

BI-RADS

Breast Imaging Reporting and Data System

The standardized scoring system developed by the American College of Radiology (ACR) to categorize mammography, breast ultrasound, and MRI findings from 0 (incomplete) to 6 (proven malignancy).

Clinical Relevance:

BI-RADS 1 = Negative; BI-RADS 2 = Benign; BI-RADS 3 = Probably benign (short-interval follow-up); BI-RADS 4 = Suspicious (biopsy recommended); BI-RADS 5 = Highly suggestive of malignancy (biopsy required).

Related:
Acronyms & Short Forms

BCS

Breast Conserving Surgery (Lumpectomy)

Surgical excision of the primary malignant breast tumor along with a margin of healthy normal surrounding tissue, preserving the remaining breast contour and structure.

Clinical Relevance:

Standard surgical option for early-stage operable breast cancer when combined with postoperative radiotherapy, demonstrating equivalent overall survival to total mastectomy.

Related:
Acronyms & Short Forms

MRM

Modified Radical Mastectomy

Surgical removal of the entire breast parenchyma, nipple-areola complex, and axillary lymph nodes (Levels I & II) while preserving the underlying pectoralis major muscle.

Clinical Relevance:

The most commonly performed mastectomy procedure in Bangladesh for multicentric disease, large tumors, or where postoperative radiation therapy is unavailable or contraindicated.

Related:
Acronyms & Short Forms

SLNB

Sentinel Lymph Node Biopsy

Identification, surgical removal, and histological examination of the first lymph node(s) receiving drainage from the primary breast tumor using radioactive tracer or isosulfan/methylene blue dye.

Clinical Relevance:

Spares patients without nodal metastasis from comprehensive axillary clearance, dramatically reducing the risk of chronic upper-limb lymphedema.

Related:
Acronyms & Short Forms

ALND

Axillary Lymph Node Dissection

Surgical clearance of Levels I and II axillary fat pads containing between 10 to 20 or more lymph nodes for staging and local regional disease control.

Clinical Relevance:

Indicated when pre-operative biopsy or sentinel node evaluation demonstrates extensive nodal metastasis. Carries a higher incidence of lymphedema and numbness.

Related:
Acronyms & Short Forms

NAC

Neoadjuvant Chemotherapy

Systemic chemotherapy given before primary surgical intervention to shrink large primary tumors and eradicate occult micrometastases.

Clinical Relevance:

Downstages tumors to permit breast-conserving surgery instead of mastectomy and provides real-time in vivo assessment of tumor drug sensitivity.

Related:
Acronyms & Short Forms

pCR

Pathological Complete Response

The total absence of viable invasive cancer cells in surgical breast tissue and regional axillary nodes upon histological examination after neoadjuvant systemic therapy (ypT0/is ypN0).

Clinical Relevance:

A premier surrogate endpoint strongly predicting favorable event-free and overall survival, especially in HER2-positive and triple-negative breast cancer subtypes.

Related:
Acronyms & Short Forms

IHC

Immunohistochemistry

A laboratory diagnostic staining technique using antigen-specific antibodies linked to enzymes or fluorophores to detect receptor protein expression in formalin-fixed paraffin-embedded tissue sections.

Clinical Relevance:

Standard technique for establishing ER, PR, HER2 (0 to 3+), and Ki-67 proliferation status to classify tumors into intrinsic molecular subtypes.

Related:
Acronyms & Short Forms

FISH

Fluorescence In Situ Hybridization

A molecular cytogenetic technique utilizing fluorescently labeled DNA probes that hybridize specifically to the ERBB2 gene locus on chromosome 17 to determine copy number amplification.

Clinical Relevance:

The definitive confirmatory test for equivocal (IHC 2+) HER2 breast cancer cases to determine whether the patient is a candidate for Trastuzumab/HER2 targeted agents.

Related:
Acronyms & Short Forms

SERM

Selective Estrogen Receptor Modulator

Synthetic pharmacological compounds that act as estrogen receptor antagonists in breast tissue while exerting estrogenic agonist effects in other organs like bone and endometrium.

Clinical Relevance:

Tamoxifen is the benchmark SERM, prescribed for 5 to 10 years to reduce recurrence and mortality in both premenopausal and postmenopausal ER+ breast cancer.

Related:
Acronyms & Short Forms

AI

Aromatase Inhibitor

A class of oral endocrine medications (Letrozole, Anastrozole, Exemestane) that inhibit the aromatase cytochrome P450 enzyme, halting peripheral androgen conversion into estrogens.

Clinical Relevance:

Standard first-line adjuvant hormonal treatment for postmenopausal women with hormone receptor-positive breast cancer, superior to Tamoxifen in this population.

Related:
Acronyms & Short Forms
CDK4/6i

CDK4/6 Inhibitor

Cyclin-Dependent Kinase 4 and 6 Inhibitors

A class of targeted therapeutic kinase inhibitors (Palbociclib, Ribociclib, Abemaciclib) that block enzymes regulating cell cycle progression from G1 to S phase.

Clinical Relevance:

Combined with endocrine therapy to substantially prolong progression-free and overall survival in hormone receptor-positive, HER2-negative metastatic and high-risk early breast cancer.

Related:
Acronyms & Short Forms

ADC

Antibody-Drug Conjugate

A biopharmaceutical class consisting of a monoclonal antibody linked via a chemical linker to a cytotoxic drug payload (e.g., T-DXd / Trastuzumab Deruxtecan, T-DM1, Sacituzumab Govitecan).

Clinical Relevance:

Delivers potent chemotherapy selectively into cancer cells expressing targeted surface receptors (HER2, Trop-2), revolutionizing outcomes in HER2-positive, HER2-low, and TNBC patients.

Related:
Acronyms & Short Forms

NGS

Next-Generation Sequencing

High-throughput massively parallel sequencing technologies allowing rapid, simultaneous sequencing of millions to billions of DNA/RNA fragments across targeted gene panels or whole exomes.

Clinical Relevance:

Enables comprehensive genomic profiling for actionable somatic mutations (PIK3CA, ESR1, BRCA1/2), copy number changes, and research discoveries featured in the TCGA/BCPBD portals.

Related:
Acronyms & Short Forms

TMB

Tumor Mutational Burden

The total number of non-synonymous somatic mutations detected per megabase (mut/Mb) of sequenced tumor genomic coding region.

Clinical Relevance:

High TMB (≥10 mutations/Mb) generates tumor neoantigens that trigger host immune responses, serving as an FDA-approved predictive biomarker for immune checkpoint inhibitors (e.g., Pembrolizumab).

Related:
Acronyms & Short Forms
CNA

CNA / CNV

Copy Number Alteration / Variation

Somatic chromosomal changes resulting in an abnormal number of copies of specific DNA segments, categorized as high-level amplifications, gains, shallow deletions, or deep homozygous deletions.

Clinical Relevance:

Drives oncogene overexpression (e.g., ERBB2, CCND1, MYC amplification) and tumor suppressor loss (e.g., PTEN, RB1 deletions) tracked across the BCPBD and TCGA portals.

Related:
Acronyms & Short Forms

SNV

Single Nucleotide Variant

A variation or mutation involving a change in a single nucleotide base (A, C, G, or T) in a genomic DNA sequence.

Clinical Relevance:

The most prevalent form of somatic cancer mutations, responsible for activating hotspots in oncogenes like PIK3CA and inactivating mutations in TP53.

Related:
Acronyms & Short Forms

Indel

Insertion-Deletion Mutation

A genomic mutation characterized by the insertion or deletion of small segments of nucleotide bases (1 to <50 bp) in the genomic DNA sequence.

Clinical Relevance:

Frequently causes frameshift alterations in tumor suppressor genes, leading to premature truncation of proteins like BRCA1 and BRCA2.

Related:
Acronyms & Short Forms
FPKM

FPKM / TPM

Fragments Per Kilobase Million / Transcripts Per Kilobase Million

Normalized expression metrics in RNA-sequencing that standardize raw read counts by adjusting for both gene transcript length and total sequenced library depth.

Clinical Relevance:

Employed throughout the TCGA and BCPBD gene expression analysis modules to accurately compare mRNA expression levels between tumor and normal tissues.

Related:
Acronyms & Short Forms

OS

Overall Survival

The duration of time from the date of cancer diagnosis or the initiation of treatment to the date of death from any cause.

Clinical Relevance:

Universally acknowledged as the premier gold-standard clinical outcome metric in cancer epidemiology, clinical trials, and Kaplan-Meier analyses.

Related:
Acronyms & Short Forms

DFS

Disease-Free Survival

The length of time following curative-intent primary treatment (e.g. surgery + adjuvant therapy) that a patient survives without any sign of cancer recurrence (local or distant).

Clinical Relevance:

Key primary outcome measure evaluating the curative potential of adjuvant surgical, systemic, and radiotherapeutic treatments.

Related:
Acronyms & Short Forms

PFS

Progression-Free Survival

The duration of time during and following cancer therapy that a patient lives with the disease without the tumor progressing, enlarging, or spreading further.

Clinical Relevance:

Critical efficacy benchmark in clinical trials of advanced and metastatic breast cancer assessing the durability of targeted therapies and chemotherapy.

Related:
Acronyms & Short Forms

HR

Hazard Ratio (or Hormone Receptor)

In survival statistics (Cox proportional hazards models), the ratio of the hazard (risk) rate in an exposed/treated cohort relative to an unexposed/control cohort. In clinical biology, also commonly denotes Hormone Receptor (ER/PR).

Clinical Relevance:

An HR < 1.0 demonstrates that a therapeutic intervention reduces risk of relapse or death; an HR > 1.0 indicates elevated risk. Core parameter in BCPBD survival models.

Related:
Acronyms & Short Forms

OR

Odds Ratio

A statistical ratio quantifying the strength of association between an exposure (e.g. high BMI, parity, diabetes) and an outcome (breast cancer occurrence) in case-control epidemiological studies.

Clinical Relevance:

An OR = 1.0 means no association; OR > 1.0 indicates exposure is associated with higher disease odds. Central to the BCPBD 2x2 contingency table calculator.

Related:
Acronyms & Short Forms
CI

CI (95% CI)

95% Confidence Interval

A computed statistical range that has a 95% probability of containing the true population parameter (e.g. true Odds Ratio or Hazard Ratio).

Clinical Relevance:

Indicates precision of an estimate. If the 95% CI of an Odds Ratio or Hazard Ratio does not cross 1.0, the finding is regarded as statistically significant.

Related:
Acronyms & Short Forms

BMI

Body Mass Index

An anthropometric calculation assessing body fat based on weight and height, calculated as weight in kilograms divided by the square of height in meters (kg/m²).

Clinical Relevance:

High BMI (overweight ≥25, obesity ≥30) is a validated risk factor for postmenopausal breast cancer and worse prognostic outcomes due to peripheral estrogen production in adipose tissue.

Related:
Acronyms & Short Forms

WHR

Waist-to-Hip Ratio

The ratio of the circumference of the waist to that of the hips, measuring central/abdominal adiposity and visceral fat distribution.

Clinical Relevance:

WHR > 0.85 in women indicates visceral adiposity, which is strongly linked with systemic metabolic inflammation, insulin resistance, and increased breast cancer risk in South Asian cohorts.

Related:
Acronyms & Short Forms
BP

BP (Systolic / Diastolic)

Blood Pressure

The hydrostatic pressure exerted by circulating blood upon arterial walls, recorded as Systolic (peak pressure during ventricular contraction) over Diastolic (minimum pressure during relaxation).

Clinical Relevance:

Tracked in the BCPBD clinical registry. Hypertension is an important comorbidity impacting cardiovascular safety when prescribing anthracyclines and anti-HER2 therapies.

Related:
Acronyms & Short Forms
RBS

RBS / FBS

Random Blood Sugar / Fasting Blood Sugar

Blood glucose concentration measured either without regard to meal intake (Random Blood Sugar) or after an overnight fast of 8+ hours (Fasting Blood Sugar).

Clinical Relevance:

Screening tests for impaired glucose tolerance and diabetes mellitus; chronic hyperglycemia promotes insulin and IGF-1 signaling that may drive oncogenesis.

Related:
Acronyms & Short Forms

HbA1c

Glycated Hemoglobin A1c

A biochemical test measuring the percentage of hemoglobin bound to glucose in circulating red blood cells, reflecting average blood glucose control over the preceding 8-12 weeks.

Clinical Relevance:

A value ≥6.5% confirms diabetes mellitus. Poor glycemic control during chemotherapy is associated with increased toxicity, infection risk, and adverse survival.

Related:
Acronyms & Short Forms
Lipid Profile

HDL / LDL / TG / TC

High-Density Lipoprotein, Low-Density Lipoprotein, Triglycerides, Total Cholesterol

A complete blood panel measuring circulating cholesterol and lipids. LDL is atherogenic ('bad cholesterol'), HDL is cardio-protective ('good cholesterol'), and TG reflects neutral fat storage.

Clinical Relevance:

Atherogenic ratios (TG/HDL, TC/HDL, LDL/HDL) recorded in the BCPBD dataset serve as markers of dyslipidemia, chronic inflammation, and breast cancer metabolic cofactors.

Related:
Acronyms & Short Forms

CAD

Coronary Artery Disease

Impaired myocardial blood flow caused by atherosclerotic narrowing or occlusion of coronary arteries.

Clinical Relevance:

Recorded in the BCPBD patient questionnaire. An essential cardio-oncology consideration before administering cardiotoxic chemotherapy regimens (such as Doxorubicin).

Related:
Acronyms & Short Forms

BSE

Breast Self-Examination

A regular monthly self-inspection and palpation performed by a woman to check her breasts for lumps, skin puckering, changes in shape, or nipple discharge.

Clinical Relevance:

A vital, cost-effective early detection awareness practice actively championed in low-resource and rural settings across Bangladesh.

Related:
Acronyms & Short Forms

CBE

Clinical Breast Examination

A comprehensive physical breast inspection and manual palpation conducted by a physician, surgeon, or trained healthcare professional.

Clinical Relevance:

Key frontline screening modality in low- and middle-income countries where routine nationwide population mammographic screening programs are not widely accessible.

Related:
Acronyms & Short Forms
EBRT

EBRT / RT

External Beam Radiation Therapy

The application of high-energy ionizing photons (X-rays) delivered from a linear accelerator outside the body to destroy microscopic residual cancer cells in the breast or regional lymph nodes.

Clinical Relevance:

Standard adjuvant therapy after breast-conserving surgery or in high-risk post-mastectomy cases, reducing loco-regional recurrence by >50%.

Related:
Acronyms & Short Forms

WBI

Whole Breast Irradiation

Adjuvant external radiation therapy encompassing the entire mammary gland tissue following breast-conserving surgery (lumpectomy).

Clinical Relevance:

Mandatory component of breast conservation therapy (BCS) ensuring local disease recurrence rates match those of mastectomy.

Related:
Acronyms & Short Forms

PMRT

Post-Mastectomy Radiation Therapy

Adjuvant radiation targeted to the chest wall and regional draining nodal stations (supraclavicular, axillary, internal mammary) following mastectomy.

Clinical Relevance:

Standard recommendation for patients with primary tumors >5 cm (T3/T4) or involvement of 4 or more axillary lymph nodes (N2/N3).

Related:
Acronyms & Short Forms

LVI

Lymphovascular Invasion

The microscopic presence of cancer cell clusters inside the lumina of lymphatic channels or small blood vessels outside the main tumor mass.

Clinical Relevance:

An adverse pathological prognostic factor that correlates with higher axillary nodal involvement, distant metastasis, and higher recurrence risk.

Related:
Acronyms & Short Forms

PNI

Perineural Invasion

The histological observation of neoplastic cells tracking along, surrounding, or invading nerve sheaths in the breast tissue.

Clinical Relevance:

Indicates aggressive local invasion and carries higher risk of local regional relapse.

Related:
Acronyms & Short Forms
Gy

Gy (Gray)

Gray (Unit of Absorbed Radiation Dose)

The International System (SI) unit of absorbed ionizing radiation dose, defined as one joule of radiation energy absorbed per kilogram of tissue.

Clinical Relevance:

Standard breast cancer adjuvant radiation courses administer a cumulative dose of 40-50 Gy delivered in divided daily fractions (e.g., 2 Gy per fraction or hypofractionated 2.67 Gy).

Related:
Acronyms & Short Forms

TCGA

The Cancer Genome Atlas

A landmark multi-institutional genomics project that comprehensively mapped genomic mutations, copy number variations, RNA sequencing, and clinical outcomes across over 1,000 breast invasive carcinomas (TCGA-BRCA).

Clinical Relevance:

Integrated into the BCPBD portal's research tools, allowing researchers to explore survival curves, gene expression, and mutation frequencies.

Related:
Biomarkers & Subtypes

Luminal A Subtype

Luminal A Molecular Breast Cancer Subtype

The most prevalent molecular breast cancer subtype, defined by positive estrogen receptor (ER+) and progesterone receptor (PR+ ≥20%), negative HER2 (HER2-), and low proliferation index (Ki-67 <14-20%).

Clinical Relevance:

Carries the most favorable overall prognosis. Highly responsive to endocrine therapies (Tamoxifen, Letrozole); rarely requires adjuvant cytotoxic chemotherapy in node-negative disease.

Related:
Biomarkers & Subtypes

Luminal B Subtype

Luminal B Molecular Breast Cancer Subtype

Hormone receptor-positive breast cancer (ER+) that is either HER2-positive OR HER2-negative with high cell proliferation (Ki-67 ≥20%) or lower PR levels.

Clinical Relevance:

More aggressive and has a higher recurrence rate than Luminal A. Treatment often entails adjuvant chemotherapy in addition to endocrine therapy, plus anti-HER2 therapy if HER2+.

Related:
Biomarkers & Subtypes

HER2-Enriched Subtype

HER2-Enriched Molecular Breast Cancer Subtype

A subtype featuring high amplification and overexpression of the ERBB2/HER2 oncogene, usually testing negative for hormone receptors (ER-, PR-).

Clinical Relevance:

Characterized by rapid growth and higher historical recurrence rates, now effectively managed with targeted anti-HER2 regimens (Trastuzumab + Pertuzumab + chemotherapy).

Related:
Biomarkers & Subtypes

Basal-like Subtype

Basal-like Molecular Breast Cancer Subtype

An intrinsic gene expression subtype that substantially overlaps with triple-negative breast cancer (ER-, PR-, HER2-), expressing basal cytokeratins (CK5/6, CK14, CK17) and EGFR.

Clinical Relevance:

Associated with earlier age of onset, aggressive histology, visceral metastatic patterns, and frequent TP53 mutations.

Related:
Biomarkers & Subtypes
Ki-67

Ki-67 Proliferation Index

Antigen Ki-67 Cellular Proliferation Marker

A nuclear protein expressed during all active phases of the cell division cycle (G1, S, G2, M) but entirely absent in quiescent cells (G0).

Clinical Relevance:

Quantified as a percentage of positive tumor cell nuclei. A score ≥20% denotes high proliferation, distinguishing high-risk Luminal B tumors from indolent Luminal A tumors.

Related:
Biomarkers & Subtypes

BRCA1

Breast Cancer Susceptibility Gene 1

A critical tumor suppressor gene located on chromosome 17q21 encoding a protein that repairs double-strand DNA breaks via homologous recombination.

Clinical Relevance:

Hereditary germline pathogenic mutations confer up to 70% lifetime risk of breast cancer and 40% risk of ovarian cancer. Often manifests as aggressive, basal-like TNBC; highly sensitive to PARP inhibitors (Olaparib) and platinum salts.

Related:
Biomarkers & Subtypes

BRCA2

Breast Cancer Susceptibility Gene 2

A tumor suppressor gene on chromosome 13q12.3 that interacts with RAD51 to coordinate high-fidelity homologous recombination repair of DNA breaks.

Clinical Relevance:

Pathogenic mutations lead to high lifetime risk of breast and ovarian cancer in women, as well as elevated risk of male breast cancer and pancreatic cancer. Also actionable with PARP inhibitors.

Related:
Biomarkers & Subtypes

TP53

Tumor Protein P53 ('Guardian of the Genome')

A central tumor suppressor gene on chromosome 17p13 that arrests cell cycle progression to facilitate DNA repair or triggers apoptosis when damage is irreparable.

Clinical Relevance:

Mutated in ~30% of breast cancers overall and >80% of basal-like TNBC. Loss-of-function somatic mutations cause genomic instability and aggressive disease.

Related:
Biomarkers & Subtypes

PIK3CA

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Subunit Alpha

An oncogene encoding the p110α catalytic subunit of PI3K, stimulating the downstream AKT/mTOR cascade to promote cell growth, motility, and survival.

Clinical Relevance:

Mutated in 30-40% of ER+/HER2- breast cancers. Hotspot mutations (e.g. H1047R, E545K) are directly actionable with PI3K-alpha inhibitors (Alpelisib) combined with fulvestrant.

Related:
Biomarkers & Subtypes

GATA3

GATA-Binding Protein 3

A zinc-finger transcription factor vital for normal luminal epithelial cell differentiation in the mammary gland.

Clinical Relevance:

One of the most frequently mutated genes in Luminal A and Luminal B breast cancers. High GATA3 expression strongly correlates with ER positivity and favorable prognosis.

Related:
Biomarkers & Subtypes

CDH1

Cadherin 1 (E-Cadherin)

A transmembrane glycoprotein that mediates calcium-dependent intercellular adhesion, maintaining epithelial tissue architecture.

Clinical Relevance:

Biallelic loss of CDH1 through mutation or deletion is the molecular hallmark of Invasive Lobular Carcinoma (ILC), resulting in discohesive cells growing in single-file patterns.

Related:
Staging & Pathology

Cancer Stages (0 to IV)

Breast Cancer Clinical & Pathological Stages (0, I, II, III, IV)

The anatomical extent of cancer in the body: Stage 0 (non-invasive / in situ); Stage I (early, small localized tumor ≤2 cm without lymph nodes); Stage II (localized with limited node spread); Stage III (locally advanced / large tumor or multiple involved nodes); Stage IV (distant metastasis).

Clinical Relevance:

Dictates clinical management strategy: Stages I-III are treated with curative intent (surgery, radiotherapy, systemic therapy), whereas Stage IV focuses on disease control and prolonging survival.

Related:
Staging & Pathology

Nottingham Histologic Score

Nottingham Combined Histologic Grade (Elston-Ellis Modification)

The universal grading system evaluating three microscopic features: Tubule Formation (1-3), Nuclear Pleomorphism (1-3), and Mitotic Count per 10 high-power fields (1-3). Scores sum from 3 to 9.

Clinical Relevance:

Grade 1 (score 3-5, well-differentiated, slowest growing); Grade 2 (score 6-7, moderately differentiated); Grade 3 (score 8-9, poorly differentiated, highly proliferative and aggressive).

Related:
Staging & Pathology

Ductal Calcification

Microcalcifications in Breast Ducts

Microscopic calcium deposits formed within mammary ducts due to cellular secretions or necrosis of malignant cells, appearing as fine white specks or clusters on mammograms.

Clinical Relevance:

A key radiographic sign of Ductal Carcinoma In Situ (DCIS) and early non-palpable invasive ductal cancer, prompting stereotactic biopsy.

Related:
Staging & Pathology

Ductal Extension

Ductal Extension of Carcinoma

The continuous or discontinuous spread of malignant cells extending along the lumen and walls of mammary ducts beyond the central tumor mass.

Clinical Relevance:

An important parameter when assessing surgical margins in breast-conserving surgery to ensure complete excision and avoid residual disease.

Related:
Staging & Pathology

Surgical Resection Margins

Surgical Margin Status (Negative, Close, Positive)

The edge or border of tissue removed during surgery, examined microscopically after applying surgical ink. 'Negative' (no tumor cells at ink); 'Positive' (tumor cells touch inked edge); 'Close' (<1-2 mm distance).

Clinical Relevance:

The surgical guideline 'no ink on tumor' is required for invasive cancer to minimize local recurrence risk; positive margins necessitate re-excision.

Related:
Staging & Pathology

Gross vs Microscopic Pathology

Macroscopic (Gross) and Microscopic Pathological Examination

Gross pathology involves visual inspection, sizing, palpation, and specimen orientation with the naked eye. Microscopic pathology involves examining thin tissue sections stained with H&E under high magnification.

Clinical Relevance:

Gross pathology determines primary tumor dimensions and lymph node count; microscopic pathology determines histologic subtype, Nottingham grade, receptor expression, and vascular invasion.

Related:
Diagnostics & Tests

Mammography

Screening and Diagnostic Mammography

A specialized low-dose X-ray examination of the compressed breast tissue used to detect non-palpable masses, microcalcifications, and architectural distortions.

Clinical Relevance:

The most widely proven screening method for early breast cancer detection, reducing mortality by 20-30% in women aged 40-74.

Related:
Diagnostics & Tests

Breast Ultrasound (Sonography)

High-Resolution Breast Ultrasonography

An imaging modality using high-frequency sound waves to visualize breast tissue architecture without ionizing radiation.

Clinical Relevance:

Essential adjunctive tool to mammography; especially valuable in women with dense breast tissue and for distinguishing fluid-filled benign cysts from solid suspicious masses.

Related:
Diagnostics & Tests

Breast MRI

Contrast-Enhanced Magnetic Resonance Imaging of the Breast

An advanced imaging technique utilizing strong magnetic fields, radio waves, and intravenous gadolinium contrast to generate high-resolution cross-sectional breast images.

Clinical Relevance:

Recommended for high-risk surveillance (e.g. BRCA mutation carriers), assessing disease extent in invasive lobular carcinoma, and evaluating response to neoadjuvant chemotherapy.

Related:
Diagnostics & Tests

Multigene Expression Assays

Genomic Recurrence Assays (Oncotype DX, MammaPrint)

Molecular diagnostic tests measuring mRNA expression levels of panels of 21 to 70 breast cancer-related genes to quantify residual recurrence risk score.

Clinical Relevance:

Used in early-stage ER+/HER2- breast cancer to identify patients who can safely omit adjuvant chemotherapy, sparing unnecessary toxicity.

Related:
Treatments & Surgery

Trastuzumab (Herceptin)

Trastuzumab Recombinant Monoclonal Antibody

A humanized IgG1 monoclonal antibody that binds specifically to subdomain IV of the extracellular domain of the HER2 protein receptor.

Clinical Relevance:

Revolutionized HER2+ breast cancer therapy, reducing the risk of recurrence by almost 50% and significantly extending survival when administered with chemotherapy.

Related:
Treatments & Surgery

Tamoxifen

Tamoxifen Citrate Selective Estrogen Receptor Modulator

An oral selective estrogen receptor modulator (SERM) that binds competitively to estrogen receptors on breast carcinoma cells, blocking estrogen-mediated transcription.

Clinical Relevance:

The cornerstone adjuvant endocrine drug for premenopausal and postmenopausal ER+ patients, taken daily for 5 to 10 years to reduce recurrence and mortality.

Related:
Treatments & Surgery

Aromatase Inhibitors (Letrozole / Anastrozole / Exemestane)

Third-Generation Aromatase Inhibitors

Oral non-steroidal (Letrozole, Anastrozole) and steroidal (Exemestane) agents that inhibit the peripheral aromatase enzyme responsible for synthesizing estrogens in postmenopausal women.

Clinical Relevance:

First-line endocrine therapy for postmenopausal ER+ breast cancer, superior to Tamoxifen in disease-free survival.

Related:
Treatments & Surgery

Doxorubicin (Adriamycin)

Doxorubicin Hydrochloride Anthracycline Chemotherapy

A potent cytotoxic anthracycline antibiotic that intercalates into DNA base pairs and inhibits topoisomerase II, leading to DNA double-strand breaks and cell death.

Clinical Relevance:

Foundation of standard chemotherapy regimens (e.g. AC: Adriamycin + Cyclophosphamide) for moderate-to-high risk early and locally advanced breast cancer. Monitored for potential cardiotoxicity.

Related:
Treatments & Surgery

Paclitaxel / Docetaxel

Taxane Chemotherapy (Paclitaxel and Docetaxel)

Plant alkaloid-derived cytotoxic agents that bind to and stabilize beta-tubulin microtubules, blocking mitotic spindle disassembly and arresting cell division in the G2/M phase.

Clinical Relevance:

Routinely sequenced following anthracyclines (e.g., AC-T regimen) in adjuvant and neoadjuvant therapy, significantly improving disease-free and overall survival.

Related:
Treatments & Surgery

PARP Inhibitors (Olaparib / Talazoparib)

Poly (ADP-Ribose) Polymerase Inhibitors

Targeted oral medications that trap PARP enzymes on single-strand DNA breaks, exploiting 'synthetic lethality' in cancer cells with homologous recombination defects (such as BRCA1/2 mutations).

Clinical Relevance:

Approved for adjuvant treatment of high-risk HER2- early breast cancer and metastatic breast cancer harboring germline BRCA1/2 mutations.

Related:
Treatments & Surgery

Immunotherapy (Pembrolizumab)

Immune Checkpoint Inhibitor (anti-PD-1 / anti-PD-L1)

Monoclonal antibodies that block the programmed cell death-1 (PD-1) pathway on T-cells, reversing immune evasion and allowing cytotoxic T-cells to attack tumor cells.

Clinical Relevance:

Combined with chemotherapy in high-risk early triple-negative breast cancer and PD-L1-positive metastatic TNBC, substantially improving pathological complete response (pCR) and overall survival.

Related:
Treatments & Surgery

Lymphedema

Secondary Upper-Extremity Breast Cancer-Related Lymphedema

Chronic swelling of the arm, breast, or chest wall resulting from the accumulation of protein-rich lymphatic fluid due to surgical disruption or irradiation of axillary lymphatics.

Clinical Relevance:

A major survivorship complication whose incidence is drastically reduced by adopting Sentinel Lymph Node Biopsy (SLNB) in place of routine Axillary Lymph Node Dissection (ALND).

Related:
Clinical & Metabolic

Age at Menarche

Early Menarche (Age at First Menstrual Period)

The chronological age at which a female experiences her first menstrual cycle, recorded as a baseline demographic and reproductive variable in the BCPBD dataset.

Clinical Relevance:

Early menarche (<12 years old) increases lifetime cumulative exposure of breast epithelium to endogenous ovarian estrogens, modestly increasing breast cancer risk.

Related:
Clinical & Metabolic

Age at Menopause

Late Menopause & Menopausal Status

The permanent cessation of ovarian menses for 12 consecutive months. Pre-, peri-, and post-menopausal status are fundamental clinical stratifiers in BCPBD.

Clinical Relevance:

Late natural menopause (>55 years) prolongs estrogen exposure and elevates breast cancer risk. Postmenopausal status dictates the choice of endocrine therapy (Aromatase Inhibitors over Tamoxifen).

Related:
Clinical & Metabolic

Parity & Nulliparity

Obstetric Parity and Number of Full-Term Pregnancies

Parity refers to the total number of full-term pregnancies; nulliparity designates having never delivered a viable child.

Clinical Relevance:

Full-term pregnancy at an early age (<25 years) and high multiparity provide long-term protection against ER+ breast cancer by promoting terminal maturation of mammary lobules.

Related:
Clinical & Metabolic

Lactation Duration

Cumulative Lifetime Breastfeeding Duration

The total duration (in months or years) a woman has breastfed her children throughout her reproductive lifetime.

Clinical Relevance:

Extended cumulative breastfeeding (>12 months) significantly lowers lifetime breast cancer risk by inducing epithelial differentiation and suppressing ovulatory menstrual cycles.

Related:
Clinical & Metabolic

Serum Creatinine

Serum Creatinine Renal Biomarker

A breakdown product of creatine phosphate from muscle metabolism excreted by the kidneys, recorded in milligrams per deciliter (mg/dL) in the BCPBD biochemical panel.

Clinical Relevance:

Essential for evaluating baseline renal filtration (eGFR). Impaired renal clearance necessitates dose adjustments for chemotherapy agents like Cyclophosphamide, Methotrexate, and platinum salts.

Related:
Clinical & Metabolic

Oral Contraceptive & HRT Use

Exogenous Hormone Use (Oral Contraceptive Pills / Hormone Replacement Therapy)

The therapeutic ingestion of synthetic estrogens and progestins for pregnancy prevention (OCP) or relief of postmenopausal vasomotor symptoms (HRT).

Clinical Relevance:

Prolonged combined HRT and current OCP use are associated with a slight transient increase in breast cancer risk that normalizes several years after cessation.

Related:
Genomics & Research

Oncoprint Heatmap

Oncoprint Multi-Gene Genomic Matrix

A visual matrix where columns represent individual patient tumor samples and rows represent selected cancer driver genes, displaying somatic mutations, copy number amplifications, and deletions as color-coded tiles.

Clinical Relevance:

Used in the BCPBD and TCGA analytical dashboards to illustrate mutational co-occurrence, mutual exclusivity, and recurrent alteration frequencies.

Related:
Genomics & Research

Kaplan-Meier Survival Analysis

Kaplan-Meier Product-Limit Estimator

A non-parametric statistical method estimating the probability of patient survival over time, accounting for censored observations.

Clinical Relevance:

Generates survival step curves to compare prognostic differences across molecular subtypes, tumor stages, or gene expression cohorts, accompanied by log-rank test p-values.

Related:
Genomics & Research

Chi-Square Test (χ²)

Pearson's Chi-Square Test of Independence

A statistical hypothesis test assessing whether an observed distribution of categorical variables in a contingency table differs significantly from an expected null distribution.

Clinical Relevance:

Used in the BCPBD 2x2 calculator to identify significant associations between patient lifestyle or dietary risk factors and cancer incidence.

Related:
Genomics & Research

Hypoxia Score

Ragnum / Buffa / Winter Tumor Hypoxia Gene Signature

A computational gene expression score calculated from hypoxia-responsive genes, quantifying cellular oxygen deprivation within the tumor microenvironment.

Clinical Relevance:

High hypoxia scores indicate aggressive, poorly oxygenated tumors with increased angiogenesis, radioresistance, and elevated metastatic potential.

Related:
Genomics & Research

Log2 Fold Change (Log₂FC)

Binary Logarithm of Differential Gene Expression Ratio

A mathematical transformation representing the ratio of gene expression levels between two biological cohorts (e.g. tumor vs normal tissue) on a base-2 logarithmic scale.

Clinical Relevance:

A Log₂FC of +1 denotes a two-fold upregulation in tumor tissue; a Log₂FC of -1 denotes a 50% downregulation. Core metric in differential expression plots.

Related:
Genomics & Research

p-value

Statistical Significance Probability Value

The probability of obtaining test results at least as extreme as the observed results under the assumption that the null hypothesis is true.

Clinical Relevance:

A p-value < 0.05 is commonly used to reject the null hypothesis and establish statistical significance in clinical associations and genomic differential expression.

Related:
Clinical & Metabolic

Smoking Status

Cigarette / Tobacco Smoking Status

History and habit of cigarette or bidi smoking, recorded as a categorical behavioral risk variable.

Clinical Relevance:

Tobacco carcinogens induce DNA methylation alterations and increase cardiovascular and pulmonary comorbidities in cancer cohorts.

Related:
Clinical & Metabolic

Tobacco Usage

Smokeless and Chewed Tobacco Usage

Smokeless or chewed tobacco consumption (including jarda, gul, sada pata, and khaini) prevalent in South Asian demographics.

Clinical Relevance:

Demonstrates high prevalence in Bangladeshi female cohorts; acts as a potent chemical carcinogen causing localized mucosal and systemic toxicity.

Related:
Clinical & Metabolic

Alcohol Consumption

Alcohol Intake Status

History and frequency of alcohol consumption among study participants.

Clinical Relevance:

Established modifiable breast cancer risk factor that elevates circulating endogenous estrogens and disrupts hepatic folate metabolism.

Related:
Clinical & Metabolic

Athlete / Intensive Training

Athletic Conditioning and High Physical Activity

Engagement in competitive athletics or sustained high-intensity physical conditioning.

Clinical Relevance:

Protective lifestyle phenotype associated with lowered adiposity, reduced circulating insulin-like growth factors (IGF-1), and lower systemic inflammation.

Related:
Clinical & Metabolic

Fish Oil Supplementation

Dietary Fish Oil and Marine Omega-3 Intake

Dietary intake of marine fish oil providing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

Clinical Relevance:

Exhibits anti-inflammatory, anti-thrombotic, and triglyceride-lowering effects across metabolic and cardiovascular profiles.

Related:
Biomarkers & Subtypes

ER Status (Estrogen Receptor)

Estrogen Receptor Positive / Negative Status

Immunohistochemical determination of nuclear estrogen receptor expression in breast tumor cells.

Clinical Relevance:

Determines responsiveness to targeted hormonal/endocrine therapies (Tamoxifen, Letrozole) and stratifies clinical prognosis.

Related:
Biomarkers & Subtypes

Breast Cancer Molecular Subtypes (BC Types)

Intrinsic Molecular Breast Cancer Subtypes

Classification of breast carcinomas based on IHC expression of ER, PR, and HER2 into Luminal A, Luminal B, HER2-enriched, and Triple-Negative (TNBC).

Clinical Relevance:

Essential for tailoring precision oncology regimens, predicting treatment sensitivity, and estimating distant recurrence risks.

Related:
Staging & Pathology

Cancer Cells in Biopsy

Malignant Cell Detection in Diagnostic Biopsy

Microscopic cytological or histological detection of malignant epithelial cells in fine needle aspiration (FNAC) or core needle biopsy specimens.

Clinical Relevance:

Definitive diagnostic evidence distinguishing benign breast disease from invasive carcinoma before definitive surgery.

Related:
Treatments & Surgery

Prescribed Drugs / Regimen

Prescribed Chemotherapeutic and Endocrine Drug Regimens

Systemic pharmacological regimens administered to breast cancer patients, including AC-T (Doxorubicin, Cyclophosphamide, Paclitaxel), Carboplatin, and Letrozole/Tamoxifen.

Clinical Relevance:

Characterizes therapeutic patterns and standard-of-care medication implementation across the cohort.

Related:
Treatments & Surgery

Treatment Start Year

Year of Oncology Treatment Initiation

The specific calendar year in which active medical, surgical, or radiation oncology treatment was initiated.

Clinical Relevance:

Enables longitudinal trend assessment, time-to-treatment analysis, and survival interval calculations.

Related:
Clinical & Metabolic

Family History with Diabetes

Familial Predisposition to Type 2 Diabetes

Presence of diagnosed Type 2 Diabetes Mellitus in first-degree (parents, siblings) or second-degree biological relatives.

Clinical Relevance:

Reflects inherited metabolic vulnerability, insulin resistance predisposition, and shared environmental determinants.

Related:
Clinical & Metabolic

Family History with Hypertension

Familial Predisposition to Essential Hypertension

Presence of chronic essential hypertension in first-degree biological relatives.

Clinical Relevance:

Key indicator of genetic cardiovascular susceptibility and arterial stiffness interacting with metabolic syndrome.

Related:
Clinical & Metabolic

Employment Status (Formal Service)

Formal Salaried Employment vs. Homemaker

Categorization of formal salaried job holder status (government service, teaching, corporate, healthcare, garments) versus non-salaried homemaker / housewife.

Clinical Relevance:

Critical socioeconomic determinant reflecting occupation type, daytime physical activity, daily routine, and systemic healthcare accessibility.

Related: